Document:

Exhibit 10.1

 

Global Eagle Entertainment
Inc.

4553 Glencoe Avenue,
Suite 300

Marina Del Ray, CA
90292

 

May 9, 2016

 

EMC HoldCo 2 B.V.

ABRY Partners II, LLC

111 Huntington Avenue, 29th Floor

Boston, MA 02199

Attn: Tomer Yosef-Or

  

Ladies and Gentlemen:

 

Reference is made to
that certain Interest Purchase Agreement, dated as of the date hereof (the “Purchase Agreement”), by and between
EMC Acquisition Holdings, LLC, a Delaware limited liability company (“Seller”), and Global Eagle Entertainment
Inc., a Delaware corporation (“GEE”). Capitalized terms used in this letter agreement (this “Agreement”)
and not otherwise defined herein shall have the meanings set forth in the Purchase Agreement.

 

By execution below,
simultaneous with the execution of the Purchase Agreement, each of GEE and EMC HoldCo 2 B.V. (the “Stockholder”)
agrees as follows:

 

1.Board
Nominee. a)Until the earliest of (u) such date that the Stockholder holds less than
5% of GEE’s outstanding shares of common stock, (v) the consummation by the Stockholder or any of its Affiliates (as defined
below) of a Competitive Transaction (as defined below), (w) the date that any partner, member or employee of the Stockholder or
any of its Affiliates becomes a member of the board of directors, a board observer or executive officer of any competitor of GEE
or any of its subsidiaries, (x) GEE sells all or substantially all of its assets, (y) GEE participates in any merger, consolidation
or similar transaction following the consummation of which, the stockholders of GEE immediately prior to the consummation of such
transaction hold less than 50% of all of the outstanding common stock or other securities entitled to vote for the election of
directors of the surviving or resulting entity in such transaction, and (z) stockholder’s written notice to GEE that it desires
to terminate its rights pursuant to Section 1 (such date, the “Termination Date”), the Stockholder shall have
the right (but not the obligation) to nominate one (1) individual (the “Nominee”) to stand for election as a
member of GEE’s Board of Directors (the “GEE Board”), so long as such Nominee (A) is not prohibited or
disqualified from serving as a director of the GEE Board pursuant to any rule or regulation of the U.S. Securities and Exchange
Commission or The NASDAQ Stock Market LLC or by applicable law, (B) satisfies all applicable governance guidelines or policies
of GEE, as in effect from time to time, and (C) is reasonably satisfactory to the GEE Board in its good faith judgement. In the
event that a Nominee does not meet any of the foregoing requirements, the Stockholder shall have the right to designate a different
individual as a Nominee until a Nominee satisfies all of such requirements. GEE hereby agrees that each of Tomer Yosef-Or, C.J.
Brucato and Jay Grossman is deemed to satisfy all of such requirements. On the Closing Date, in accordance with the Certificate
of Incorporation of GEE as in effect from time to time (the “GEE Certificate”), GEE shall take all action necessary
to appoint the Nominee as a Class III Director on the GEE Board with a term expiring at GEE’s 2017 annual meeting of stockholders.
Thereafter, until the Termination Date, at any annual or special meeting of stockholders of GEE at which that class of directors
is up for election, GEE shall nominate such Nominee as is designated by the Stockholder to stand for such election in accordance
with the foregoing and the GEE Certificate. The designation by the Stockholder of such Nominee shall be made by the Stockholder
providing written notice of the name of such Nominee to GEE not less than 120 days prior to each meeting of stockholders at which
that class of directors is up for election (assuming for these purposes that each annual meeting shall be held on the anniversary
of the prior year’s annual meeting, and in the case of any special meeting at which that class of directors is up for election,
such written notice shall be provided not later than the later of (A) such 120 days prior to such special meeting or (B) the seventh
day following the day on which public announcement of the special meeting is first made by GEE). For purposes of this Agreement,
“Affiliates” means, in addition to any Person otherwise constituting an Affiliate under the definition of such term
in the Purchase Agreement, for the avoidance of doubt, (i) ABRY Partners, LLC (“ABRY LLC”) and its current and
future Affiliates, (ii) any entity managed by ABRY LLC now or in the future and any current or future Affiliates of such entity
and (iii) any entity in which ABRY LLC now or in the future owns a direct or indirect interest.

 

     

     

    

 

(b)The
Stockholder shall cause any Nominee who is a member of the GEE Board, at all times, to be mindful of and act in accordance with
the Nominee’s fiduciary duties to all of GEE’s stockholders and the Nominee’s duty of loyalty to GEE, including,
without limitation, with respect to corporate opportunities and conflicts of interest. The parties hereto acknowledge and agree
that a Nominee may abstain from a particular vote of the GEE Board in the event such Nominee determines it would be appropriate
to do so due to a conflict of interest. 

 

(c)The
Stockholder acknowledges and agrees that the Nominee, as a member of the GEE Board, will be recused or otherwise excluded or omitted
from portions or entireties of meetings of the GEE Board (and shall not receive any information regarding acquisition or corporate
development activities of GEE and its subsidiaries) if the Stockholder or any of its Affiliates is reviewing or evaluating any
potential acquisition, investment or other transaction involving a company or business that competes with any business then engaged
in (or contemplated to be engaged in) by GEE or any of its subsidiaries (a “Competitive Transaction”); provided
that such recusal or exclusion and the withholding of such information shall only apply during the time the Stockholder or any
of its Affiliates is evaluating or reviewing any such Competing Transaction and for 90 days thereafter. Notwithstanding the foregoing,
the Stockholder agrees to provide GEE’s General Counsel with prompt written notice of any such Competitive Transaction, in
accordance with Section 11.7 of the Purchase Agreement.

 

(d)Immediately
following the Termination Date, the Stockholder will cause the Nominee to (i) no longer attend meetings of the GEE Board and (ii)
resign as a member of the GEE Board.

 

(e)Upon
the designation of any Nominee, the Stockholder shall sign the Confidentiality Agreement attached hereto as Exhibit A (the “Confidentiality
Agreement”). 

 

     2

     

    

 

(f)The
Stockholder acknowledges and agrees that, except as otherwise set forth in this Agreement, the Nominee will only receive information
that the members of the GEE Board receive and that the Nominee will have no rights to receive or request information that is not
otherwise provided to the entire GEE Board.

 

(g)The
Stockholder acknowledges and agrees that the Nominee will be entitled to receive any regular director fees normally paid in cash
or securities to all non-employee members of the GEE Board.

 

(h)The
Stockholder shall, and shall cause the Nominee to, timely provide GEE with accurate and complete information relating to the Stockholder
and the Nominee that is required to be disclosed by GEE under the Securities Act and/or the Securities Exchange Act or GEE’s
charter and bylaws, including such information required to be furnished by GEE with respect to the Nominee in a proxy statement
pursuant to Rule 14a-101 promulgated under the Securities Exchange Act.  In addition, at GEE’s request, the Stockholder
shall cause the Nominee to promptly complete and execute GEE’s director and officer questionnaire prior to being admitted
to the GEE Board or standing for reelection at an annual meeting of stockholders or at such other time (and such other information)
as may be reasonably requested by GEE.

 

(i)The
Nominee shall be subject to all of the requirements and restrictions of GEE and the GEE Board applicable to GEE directors from
time to time, including, without limitation, GEE’s Code of Ethics and insider trading policy.

 

2.Standstill.b)
Until the expiration of six (6) months after the Termination Date (such period, the “Standstill Period”), the
Stockholder agrees that without the prior written consent of the GEE Board, none of the Stockholder or its Affiliates will in any
manner, directly or indirectly, (i) by purchase or otherwise, acquire, or propose or agree to acquire, ownership (of record or
beneficially) of any securities issued by GEE or any direct or indirect rights (including, without limitation, any convertible,
derivative or synthetic securities) or options to acquire (or otherwise act in concert with any person which so acquires, offers
to acquire or agrees to acquire) such ownership (other than solely from an action by GEE such as a stock split, dividend or recapitalization;
any rights granted to all stockholders of GEE, or any GEE securities that may be issued to the Stockholder as part of the Deferred
Consideration Amount under the Purchase Agreement; or in connection with Board service by the Nominee); (ii) submit any proposal
for, or otherwise offer to enter into, a transaction with GEE involving the acquisition (by merger, tender offer, purchase, statutory
share exchange or otherwise) of ownership (including, but not limited to, beneficial ownership) of any securities issued by GEE;
(iii) acquire or agree to acquire or effect control of GEE or directly or indirectly form, join, participate or encourage the formation
of any group (other than with its Affiliates) within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”) with respect to any voting securities of GEE or in order to acquire or affect control
of GEE; (iv) make, or in any way participate, directly or indirectly in any “solicitation” of proxies to vote (as
such terms are used in the rules of the Securities Exchange Commission) or become a participant in any proxy solicitation
or seek to advise or influence any person with respect to the voting of any securities issued by GEE; or (v) initiate, propose
or solicit votes for any stockholder proposal or induce or attempt to induce any other person to initiate any stockholder proposal
(other than any stockholder proposals recommended by the GEE Board); (vi) call or seek to have called any meeting of the stockholders
of GEE or execute any written consent in lieu of a meeting of holders of any securities of GEE; (vii) other than the Nominee, seek
election or seek to place a representative on the GEE Board or seek the removal of any member of the GEE Board, in any case alone
or in concert with others; (viii) otherwise, directly or indirectly, alone or in concert with others, seek to control the management,
Board or policies of GEE; or (ix) make any public announcement with respect to any of the foregoing. 

 

     3

     

    

 

(b)Notwithstanding
the foregoing clause (a), the Standstill Period shall terminate and the restrictions on the Stockholder set forth in clause (a)
above shall have no further force and effect in the event that GEE files a petition in bankruptcy or for similar relief, is adjudicated
bankrupt or insolvent, consents to the appointment of a receiver or similar official, makes a general assignment for the benefit
of its creditors, or a bankruptcy petition with regard to GEE is not discharged or denied within 90 days.

 

3.Remedies.
c) In the event that any covenant or agreement in this Agreement is not performed in accordance with its terms, each party hereto
agrees that, in addition to any other remedy at law or in equity, the non-breaching party will have the right to an injunction,
temporary restraining order, specific performance or other equitable relief in any court of competent jurisdiction enjoining any
such breach and enforcing specifically the terms and provisions hereof. Each party hereto agrees not to oppose the granting of
such relief in the event a court determines that such a breach has occurred, and to waive any requirement for the securing or posting
of any bond in connection with such remedy.

 

(b)All
rights, powers and remedies provided under this Agreement or otherwise available in respect hereof at law or in equity shall be
cumulative and not alternative, and the exercise or beginning of the exercise of any thereof by any party shall not preclude the
simultaneous or later exercise of any other such right, power or remedy by such party.

 

4.Effectiveness
of this Agreement. This Agreement shall become effective only upon the Closing under the Purchase Agreement and shall have
no force or effect until such time or in the event the Closing does not occur. The provisions of Section 1 of this Agreement shall
continue in effect until the Termination Date or such other time period specified in Section 1, at which time such provisions of
Section 1 of this Agreement shall terminate and be of no further force or effect. Sections 2 and 3 of this Agreement shall terminate
upon the termination of the Standstill Period, at which time Sections 2 and 3 shall be of no further force and effect. At the time
that Sections 1, 2 and 3 of this Agreement have terminated, this entire Agreement shall be deemed terminated and shall have no
further force and effect.

 

5.Miscellaneous.
d) This Agreement may not be amended, supplemented or modified except in writing, duly executed by all of the parties.

 

(b)This
Agreement and the Confidentiality Agreement constitute the entire agreement of the parties with respect to the subject matter hereof.
Each of the parties represents that they has been advised by counsel in connection with their review, execution and delivery of
this Agreement.

 

     4

     

    

 

(c)This
Agreement is made in New York and shall be governed by and construed in accordance with the internal substantive laws of the State
of New York.

 

(d)This
Agreement may be executed in more than one counterpart. Each such counterpart shall be deemed an original and all counterparts,
taken together, shall constitute one and the same instrument.

 

(e)Neither
this Agreement nor any rights or obligations hereunder shall be assigned by any party without the prior written consent of the
other party. 

 

[Signature Page to Follow]

 

     5

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be executed in multiple originals by their authorized officers, all as of the date and
year first written above.

 

	 	GEE:
	 	 	 
	 	GLOBAL EAGLE ENTERTAINMENT INC.
	 	 	 
	 	 	 
	 	By:  	/s/ David M. Davis
	 	 	Name: David M. Davis
	 	 	Title: Chief Executive Officer

 

    
Signature Page to ABRY Nomination Letter Agreement

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be executed in multiple originals by their authorized officers, all as of the date and
year first written above.

 

	 	STOCKHOLDER:
	 	 	 
	 	EMC HOLDCO 2 B.V.
	 	 	 
	 	 	 
	 	By:  	/s/ Tomer Yosef-Or
	 	 	Name: Tomer Yosef-Or
	 	 	Title: Class B Director

 

    
Signature Page to ABRY Nomination Letter Agreement

     

    

 

 

EXHIBIT A

 

[DATE]

 

Re: Confidential Information of Global Eagle
Entertainment Inc.

 

 

EMC HoldCo 2 B.V.

ABRY Partners II, LLC

111 Huntington Avenue, 29th Floor

Boston, MA 02199

Attn: Tomer Yosef-Or

 

Dear Mr. Yosef-Or:

 

In connection with
the designation of [_______] as a nominee (“Nominee”) to the Board of Directors (the “Board”) of Global
Eagle Entertainment Inc. (the “Company”) after the Nominee’s election to the Board in accordance with the Company’s
second amended and restated certificate of incorporation, the Nominee may make available to you certain information concerning
the business and properties of the Company, including copies of all materials provided to the Nominee.

 

1.                 
By your execution of this letter agreement, you agree to treat any non-public information (whether oral or written,
or electronic media) concerning the financial data, strategic business plans, forecasts, reports, analyses and other non-public,
proprietary and confidential information concerning the Company and its subsidiaries, which has been or will be furnished to you
by or on behalf of the Company or the Nominee, whether or not designated as non-public and/or confidential, (herein collectively
referred to as “Confidential Information”) in accordance with the provisions of this letter agreement, and to take
or refrain from taking certain actions hereinafter set forth.

 

2.                 
You also hereby agree that you shall safeguard the Confidential Information and use the Confidential Information
solely within the scope of assisting the Nominee in the Nominee’s duties as member of the Board and for the benefit of the
Company, that the Confidential Information will be kept confidential by you, and that you will not disclose any of the Confidential
Information in any manner whatsoever; provided, however, that you may make any disclosure of such information without being deemed
to be in breach of this letter agreement (a) to your (i) employees and officers and (ii) with prior notice to the Company, your
counsel and advisors provided that such counsel and advisors are each subject to a duty of confidentiality consistent with applicable
securities laws and regulations (recipients under clauses (i) and (ii), collectively, the “Representatives”) who need
to receive such information in order to assist the Nominee in the Nominee’s duties as a member of the Board and for the benefit
of the Company, (b) to which the Company either by a majority of the Board or by the Chief Executive Officer of the Company gives
its prior written consent, and (c) in the event and to the extent you or any of your Representatives are required to do so by a
court of competent jurisdiction, by any governmental agency having supervisory authority over the business of the Company, you
or your Representatives, or by any administrative body or legislative body (including a committee thereof) with jurisdiction to
order you or your Representatives to divulge, disclose or make accessible such information, subject to paragraph 3 below. You shall
be responsible for any breach of this letter agreement by any of your Representatives.

 

     

     

    

 

3.                 
If you are requested or required by law, regulation or legal process (including requests for information, subpoena,
civil investigative demand or similar process) to disclose any Confidential Information, you will promptly provide the Company
with written notice of any such request or requirement, unless such notice is prohibited by law, so that the Company may seek an
appropriate protective order or consider waiving your compliance with the confidentiality provisions of this letter agreement at
Company’s sole cost. If, failing the entry of a protective order or the receipt of a waiver hereunder, you are, in the opinion
of your counsel, legally required to disclose Confidential Information, you may disclose only that portion of such information
as is legally required; provided, that you agree to use your reasonable efforts to obtain assurances that confidential treatment
will be accorded such information.

 

4.                 
You hereby acknowledge that you are aware that the United States securities laws prohibit any person who has received
from an issuer material, non-public information concerning the matters which are the subject of this letter from purchasing or
selling securities of such issuer or from communicating such information to any other person under circumstances in which it is
reasonably foreseeable that such person is likely to purchase or sell securities.

 

5.                 
At any time upon the request of the Company, you will promptly deliver to the Company or destroy (at your option)
any and all Confidential Information that has been previously provided to you, except that one copy for any such Confidential Information
may be retained by you for your records to the extent required to be retained by, and in accordance with, applicable laws and regulations.
Notwithstanding any such return or destruction of the Confidential Information, you will continue to be bound by your obligations
of confidentiality and any other obligations hereunder for the term specified herein, and in the event of any retention of Confidential
Information as permitted hereunder, your obligations of confidentiality with respect to such Confidential Information shall continue
indefinitely and survive any expiration or termination of this letter agreement.

 

In case any provision
of this letter agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining
provisions shall not in any way be affected or impaired thereby.

 

It is further understood
and agreed that any breach of this letter agreement by you would result in irreparable harm to the Company, that money damages
would not be a sufficient remedy for any such breach of this letter agreement and that the Company shall be entitled to equitable
relief, including injunction and specific performance, as a remedy for any such breach. Such remedies shall not be deemed to be
the exclusive remedies for a breach of this letter agreement but shall be in addition to all other remedies available at law or
equity to the Company.

 

This letter agreement
shall terminate and be of no further force and effect three (3) years from the last date you receive Confidential Information,
except for the provisions of Section 5 which shall survive indefinitely. This letter agreement shall be governed by and construed
in accordance with the laws of the State of New York and each party hereto agrees to submit the jurisdiction and venue of the federal
or state courts located in the City of New York. This letter agreement may not be amended except pursuant to a written agreement
duly executed by you and the Company. This letter agreement may be executed in counterparts, each of which shall be deemed an original,
but all of which together shall be deemed to be one and the same agreement.

 

     

     

    

 

Please confirm your
agreement with the foregoing by signing and returning to the undersigned an executed copy of this letter agreement.

  

 

Very truly yours,

 

 

	 	GLOBAL EAGLE ENTERTAINMENT INC.
	 	 
	 	 
	 	By	 
	 	 	Name: 

Title:

 

 

Accepted and agreed as of the date first
above written:

 

  

EMC HOLDCO 2 B.V.

 

 

	By: 	 	 
	 	Name: 	 
	 	Title: 	 

 

 

NOMINEE

 

 

	By: 	 	 
	 	Name:Exhibit 10.1

 

AGREEMENT REGARDING THE JANUARY 2014

 

COMMON STOCK PURCHASE WARRANT

 

magnegas
corporation

 

THIS AGREEMENT REGARDING
THE JANUARY 2014 COMMON STOCK PURCHASE WARRANT (the “Agreement”) dated as of May 11, 2016, is between MagneGas
Corporation, a Delaware corporation (the “Company”) and Alpha Capital Anstalt (the “Investor”),
a Liechtenstein corporation.

 

WHEREAS, in connection
with that certain Securities Purchase Agreement between the Company and the Investor dated January 21, 2014, the Company issued
to the Investor a Common Stock Purchase Warrant for 2,676,416 shares of the Company’s common stock on January 27, 2014 (the
“January 2014 Warrant”);

 

WHEREAS, the January
2014 Warrant contained a provision allowing for “cashless exercise”: (a) at the option of the Investor if there was
no effective registration statement for the shares underlying the January 2014 Warrant; or (b) automatically upon the Termination
Date;

 

WHEREAS, the Company
and the Investor wish to clarify that the January 2014 Warrant “cashless exercise” provision should always have contained
sentences clarifying that if the Company could not deliver registered shares upon settlement of the cashless exercise, the Company
is not required to pay cash in lieu of such registered shares;

 

WHEREAS, the January
2014 Warrant contained a provision that upon the occurrence of a Fundamental Transaction (as defined in the January 2014 Warrant)
the Investor would have the option to receive cash for the remaining unexercised portion of the January 2014 Warrant.

 

WHEREAS, the Company
and the Investor wish to clarify that the January 2014 Warrant should never have contained a provision for the Investor to have
the option, upon the occurrence of a Fundamental Transaction, to receive cash for the remaining unexercised portion of the January
2014 Warrant;

 

WHEREAS, in the year
ended December 31, 2014 the Investor exercised 600,000 shares of the January 2014 Warrant;

 

WHEREAS, in the year ended December 31,
2015 the Investor exercised the remaining 2,076,416 shares of the January 2014 Warrant;

 

WHEREAS, since January
27, 2014, there have been no cashless exercises of the January 2014 Warrant by the Investor;

 

WHEREAS, since January
27, 2014, no Fundamental Transaction has occurred; and

 

WHEREAS, the Company
and the Investor wish to amend the January 2014 Warrant to revise the “cashless exercise” and Fundamental Transaction
provisions retroactive to January 27, 2014.

 

NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and Investor agree as follows:

 

    	 		 

     

    

  

ARTICLE I

 

AMENDMENT TO JANUARY 2014 WARRANT

 

Section 1.1 Amendments to Cashless Exercise Provision.

 

		(a)	The following underlined and bolded words shall be added to Section 2(c) of the January 2014 Warrant:

 

If at any time after the six month anniversary of
the date of the Purchase Agreement, there is no effective Registration Statement registering, or no current prospectus available
for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time
by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal
to the quotient obtained by utilizing the formula below. The Company is not required to pay cash if it can only deliver upon
settlement of a non-Termination Date “cashless exercise” Warrant Shares that are not registered under the Securities
Act. The formula consists of dividing [(A-B) (X)] by (A), where

 

(A) = the VWAP on the Trading Day immediately preceding
the date on which Holder elects to exercise this Warrant by means of a “cashless exercise,” as set forth in the applicable
Notice of Exercise;

 

(B) = the Exercise Price of this Warrant, as adjusted
hereunder; and

 

(X) = the number of Warrant Shares that would be issuable
upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather
than a cashless exercise.

 

Notwithstanding anything herein to the contrary, on
the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c). The
Company is not required to pay cash if it can only deliver upon settlement of the Termination Date “cashless exercise”
Warrant Shares that are not registered under the Securities Act.

 

		(b)	The following words that have a strikethrough and are bolded shall be deleted from Section 5(f) of the January 2014 Warrant:

 

The Holder acknowledges that the Warrant Shares acquired
upon the exercise of this Warrant, if not registered and the Holder does not utilize cashless exercise,
will have restrictions upon resale imposed by state and federal securities laws

 

Section 1.2 Amendments to Fundamental Transaction Provision.
Section 3(e) of the January 2014 Warrant shall be deleted in its entirety and replaced with the following:

 

    	 	2	 

     

    

  

e)         Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Company (without regard to any limitation
in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, at the Company’s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, the Company
or any Successor Entity (as defined below) shall purchase this Warrant from the Holder by paying, at the option of the Company,
to the Holder within ten Business Days after such request (or, if later, on the effective date of the Fundamental Transaction)
in an amount equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the effective date of such
Fundamental Transaction, either: (a) Common Stock (or corresponding Corporate Event Consideration, as applicable) valued at the
value of the consideration received by the shareholders in such Fundamental Transaction, or (y) cash. “Corporate Event Consideration”
means, collectively, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other
purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of the applicable Fundamental
Transaction had this Warrant been exercised immediately prior to the applicable Fundamental Transaction (without regard to any
limitations on the exercise of this Warrant). “Black Scholes Value” means the value of this Warrant based on the Black
and Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest
rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100
day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the
price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental
Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date. The Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this
Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of
the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares
of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this
Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares
of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose
of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which
is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor
Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this
Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.

 

    	 	3	 

     

    

  

ARTICLE II

 

MISCELLANEOUS

 

Section 2.1 Capitalized
Terms. In addition to the terms defined elsewhere in this Agreement, capitalized terms that are not otherwise defined herein
have the meanings given to such terms in the January 2014 Warrant.

 

Section 2.2 No Other
Amendments. This Agreement does not, other than as set forth in Article I of this Agreement, amend any other provision of the
January 2014 Warrant.

 

Section 2.3 Conflicts.
To the extent there is any conflict between the terms of this Agreement and the January 2014 Warrant, the terms of this Agreement
shall take precedence.

 

Section 2.4 Retroactive.
The parties agree that Sections 1.1 and 1.2 of this Agreement shall be retroactive to the date that the January 2014 Warrant was
originally issued.

 

Section 2.5 Amendment.
The provisions of the January 2014 Warrant amended herein may not be further modified or amended unless the Investor consents.

 

Section 2.6 Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

Section 2.7 Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.

 

(Signature
Pages Follow)

 

 

    	 	4	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement Regarding the January 2014 Common Stock Purchase Warrant to be duly executed by their
respective authorized signatories as of the date first indicated above.

 

	MAGNEGAS CORPORATION	 	Addresses for Notice:
	 	 	 
	By:	/s/ Luisa Ingargiola	 	Mailing Address:
	 	 	 	 
	 	
        Name: Luisa Ingargiola

        Title: Chief Financial Officer
	 	
        11885 44th Street N.

        Clearwater, FL 33762

         

        Email Address:

        Fax Number:

 

[REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK

SIGNATURE PAGE
FOR INVESTOR FOLLOWS]

 

    	 	5	 

     

    

 

 

 

[INVESTOR SIGNATURE
PAGES TO AGREEMENT REGARDING THE JANUARY 2014 COMMON STOCK PURCHASE WARRANT]

 

IN WITNESS WHEREOF,
the undersigned have caused this Agreement Regarding the January 2014 Common Stock Purchase Warrant to be duly executed by their
respective authorized signatories as of the date first indicated above.

 

	Name of investor:  Alpha Capital Anstalt	 
	 	 
	Signature of Authorized Signatory of Investor: /s/ Konrad Ackermann	 
	 	 
	Name of Authorized Signatory: Konrad Ackermann	 
	 	 
	Title of Authorized Signatory: Director	 

 

	Email Address of Authorized Signatory:	 	 
	 	 	 
	Facsimile Number of Authorized Signatory:	 	 

 

	Address for Notice to Investor:	 
	 	 
	Alpha Capital Anstalt	 
	Lettstrasse 32	 
	9490 Vaduz	 
	Principality of Liechtenstein	 

 

    	 	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]